NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers

Acquired resistance to epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a critical obstacle in the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). EHD1, a protein of the C-terminal Eps15 homology domain-containing (EHD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoyuan, Yin, Hang, Zhang, Hongxia, Hu, Jing, Lu, Hailing, Li, Chunhong, Cao, Mengru, Yan, Shi, Cai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856828/
https://www.ncbi.nlm.nih.gov/pubmed/29549343
http://dx.doi.org/10.1038/s41419-018-0447-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856828/
https://www.ncbi.nlm.nih.gov/pubmed/29549343
http://dx.doi.org/10.1038/s41419-018-0447-7

Ejemplares similares